FDA Determines Regulatory Review Period for PREVYMIS New Drug Application

Summary

The US Food and Drug Administration has officially confirmed the regulatory review period for PREVYMIS, a new drug application submitted to the FDA, and is publishing this official notice as required by law. This decision was prompted by a request from the US Patent and Trademark Office to extend a patent related to the human drug product.